JERRY L. NADLER
Osteopathic Medicine at Brambleton Ave, Norfolk, VA
License number
Virginia 0101221469
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
855 W Brambleton Ave, Norfolk, VA 23510
Phone
(757) 446-5908
(757) 446-7055 (Fax)
(757) 446-7055 (Fax)
Organization information
See more information about JERRY L. NADLER at bizstanding.comJerry L Nadler MD
825 Fairfax Ave, Norfolk, VA 23507
Industry:
Nonclassifiable Establishments
Professional information
Jerry L Nadler, Norfolk VA
Specialties:
Endocrinologist
Address:
721 Fairfax Ave, Norfolk, VA 23507
825 Fairfax Ave, Norfolk, VA 23507
855 W Brambleton Ave, Norfolk, VA 23510
825 Fairfax Ave, Norfolk, VA 23507
855 W Brambleton Ave, Norfolk, VA 23510
Education:
University of Miami, Miller School of Medicine - Doctor of Medicine
Los Angeles County-USC Medical Center - Fellowship - Endocrinology
Los Angeles County-USC Medical Center - Fellowship - Endocrinology
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Endocrinology and Metabolism (Internal Medicine)
Jerry L Nadler, Norfolk VA
Specialties:
Internal Medicine, Endocrinology and Metabolism, Endocrinology, Diabetes & Metabolism, Cardiovascular Disease
Work:
Evms Health Services
825 Fairfax Ave, Norfolk, VA 23507 Evms Health Svc
855 W Brambleton Ave, Norfolk, VA 23510 Evms Health Svc
721 Fairfax Ave, Norfolk, VA 23507 UVA Health Services Foundation
1215 Lee St, Charlottesville, VA 22908
825 Fairfax Ave, Norfolk, VA 23507 Evms Health Svc
855 W Brambleton Ave, Norfolk, VA 23510 Evms Health Svc
721 Fairfax Ave, Norfolk, VA 23507 UVA Health Services Foundation
1215 Lee St, Charlottesville, VA 22908
Education:
University of Miami(1978)
Dr. Jerry L Nadler, Norfolk VA - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
EASTERN VIRGINIA MEDICAL SCHOOL
825 Fairfax Ave STE 310, Norfolk 23507
(757) 446-8920 (Phone), (757) 624-2254 (Fax)
EVMS Strelitz Diabetes Center
855 W Brambleton Ave, Norfolk 23510
(757) 446-5908 (Phone)
825 Fairfax Ave STE 310, Norfolk 23507
(757) 446-8920 (Phone), (757) 624-2254 (Fax)
EVMS Strelitz Diabetes Center
855 W Brambleton Ave, Norfolk 23510
(757) 446-5908 (Phone)
Certifications:
Diabetes, Metabolism & Endocrinology, 1983, Internal Medicine, 1981
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
EASTERN VIRGINIA MEDICAL SCHOOL
825 Fairfax Ave STE 310, Norfolk 23507
EVMS Strelitz Diabetes Center
855 W Brambleton Ave, Norfolk 23510
Sentara Norfolk General Hospital
600 Gresham Dr, Norfolk 23507
825 Fairfax Ave STE 310, Norfolk 23507
EVMS Strelitz Diabetes Center
855 W Brambleton Ave, Norfolk 23510
Sentara Norfolk General Hospital
600 Gresham Dr, Norfolk 23507
Education:
Medical School
University of Miami / School of Medicine
Graduated: 1978
Loma Linda University Hosp
Los Angeles Cnty Usc Med Ctr
University of Miami / School of Medicine
Graduated: 1978
Loma Linda University Hosp
Los Angeles Cnty Usc Med Ctr
Treatment Of Diabetes And Disorders Associated With Visceral Obesity With Inhibitors Of Human Arachidonate 12 Lipoxygenase And Arachidonate 15-Lipoxygenase
US Patent:
2013013, May 23, 2013
Filed:
Jan 14, 2011
Appl. No.:
13/522165
Inventors:
Jerry L. Nadler - Norfolk VA, US
David Taylor-Fishwick - Norfolk VA, US
Swarup Chakrabarti - Norfolk VA, US
Anca Dobrian - Norfolk VA, US
David Taylor-Fishwick - Norfolk VA, US
Swarup Chakrabarti - Norfolk VA, US
Anca Dobrian - Norfolk VA, US
International Classification:
C12N 15/113, C12Q 1/02
US Classification:
514 44 A, 435 613, 435 612
Abstract:
A basis for understanding the arachidonate 12-lipoxygenase pathway, as well as and methods and kits for inhibiting the arachidonate 12-lipoxygenase pathway for the treatment, reversal, reduction, modulation or prevention of disease states and conditions related to type 1 or type 2 diabetes, are disclosed. Also disclosed are inflammatory forms of ALOX12 and 15, which are selectively expressed in omental adipose tissue of obese humans. Inhibitors of ALOX12 and 15 can be used to treat, prevent, modulate or reduce complications associated with increased visceral obesity and inflammation, including type 2 diabetes. Also disclosed are methods for developing selective ALOX inhibitors for treating or reducing complications associated with increased visceral obesity and inflammation.
Inhibitors Of Human 12-Lipoxygenase
US Patent:
2013009, Apr 18, 2013
Filed:
May 18, 2011
Appl. No.:
13/698340
Inventors:
David J. Maloney - Point of Rocks MD, US
Theodore Holman - Santa Cruz CA, US
Ajit Jadhav - Chantilly VA, US
Anton Simeonov - Bethesda MD, US
Jerry L. Nadler - Norfolk VA, US
Michael Holinstat - Ardmore PA, US
Theodore Holman - Santa Cruz CA, US
Ajit Jadhav - Chantilly VA, US
Anton Simeonov - Bethesda MD, US
Jerry L. Nadler - Norfolk VA, US
Michael Holinstat - Ardmore PA, US
Assignee:
The United States of America, as represented the Secretary Department of Health & Human Service - Bethesda MD
Thomas Jefferson University - Philadelphia PA
Eastern Virginia Medical School - Norfolk VA
The Regents of the University of California - Oakland CA
Thomas Jefferson University - Philadelphia PA
Eastern Virginia Medical School - Norfolk VA
The Regents of the University of California - Oakland CA
International Classification:
C07D 409/04, C07D 215/28
US Classification:
514314, 546167, 546175, 514311
Abstract:
Disclosed are inhibitors of human 12-lipoxygenase of Formula (I) or (II), wherein R, R, R, and Rare as defined herein, that are useful in treating or preventing a 12-lipoxygenase mediated disease or disorder, e.g., diabetes. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal.
Lisofylline Analogs And Methods For Use
US Patent:
2010010, Apr 29, 2010
Filed:
Aug 28, 2009
Appl. No.:
12/550124
Inventors:
Timothy L. Macdonald - Charlottesville VA, US
Jerry L. Nadler - Norfolk VA, US
Peng Cui - Guilderland NY, US
Jerry L. Nadler - Norfolk VA, US
Peng Cui - Guilderland NY, US
International Classification:
A61K 31/502, C07D 237/30
US Classification:
514248, 544237
Abstract:
Analogs of a Lisofylline (LSF), and synthetic methods for the preparation of such analogs are provided. The analogs of LSF provided have the ability to protect cell viability, particularly the ability to protect pancreatic β-cells.